Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. by Nielsen, Amalie B et al.
UCSF
UC San Francisco Previously Published Works
Title
Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic 
leukemia implicates immunosuppression in etiology.
Permalink
https://escholarship.org/uc/item/44d1h9n3
Authors
Nielsen, Amalie B
Zhou, Mi
de Smith, Adam J
et al.
Publication Date
2019-03-28
DOI
10.3324/haematol.2019.216465
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Increased neonatal level of arginase 2 in cases of 
childhood acute lymphoblastic leukemia implicates
immunosuppression in etiology
by Amalie B. Nielsen, Mi Zhou, Adam J. de Smith, Rong Wang, Lucie McCoy, Helen Hansen,
Libby Morimoto, Kirsten Grønbæch, Christoffer Johansen, Scott C. Kogan, Catherine Metayer,
Paige M. Bracci, Xiaomei Ma, and Joseph L. Wiemels 
Haematologica 2019 [Epub ahead of print]
Citation: Amalie B. Nielsen, Mi Zhou, Adam J. de Smith, Rong Wang, Lucie McCoy, Helen Hansen,
Libby Morimoto, Kirsten Grønbæch, Christoffer Johansen, Scott C. Kogan, Catherine Metayer, 
Paige M. Bracci, Xiaomei Ma, and Joseph L. Wiemels. Increased neonatal level of arginase 2 in cases 
of  childhood acute lymphoblastic leukemia implicates immunosuppression in etiology. 
Haematologica. 2019; 104:xxx
doi:10.3324/haematol.2019.216465
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.
Published Ahead of Print on March 28, 2019, as doi:10.3324/haematol.2019.216465.
	
	
1 
Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic 
leukemia implicates immunosuppression in etiology 
Amalie B. Nielsen1,2, Mi Zhou1, Adam J. de Smith1,3, Rong Wang4, Lucie McCoy5,6, Helen Hansen5, 
Libby Morimoto6, Kirsten Grønbæk2, Christoffer Johansen2, Scott C. Kogan7, Catherine Metayer6, 
Paige M. Bracci1, Xiaomei Ma4* and Joseph L. Wiemels1,3* 
 
1Department of Epidemiology and Biostatistics, University of California San Francisco 
2Department of Hematology, Rigshospitalet, Biotech Research and Innovation Centre, BRIC, 
Faculty of Health and Medical Sciences, University of Copenhagen 
3Centre for Genetic Epidemiology, Keck School of Medicine, University of Southern California 
4Department of Chronic Disease Epidemiology, School of Public Health, Yale University 
5Department of Neurosurgery, University of California San Francisco 
6Division of Epidemiology, School of Public Health, University of California Berkeley 
7Department of Laboratory Medicine, University of California San Francisco 
*Co-senior authors  
 
 
Running Title: Arginase-2 and pediatric acute lymphoblastic leukemia 
 
Corresponding Author: 
 
Joseph Wiemels, PhD 
Centre for Genetic Epidemiology, Norris Comprehensive Cancer Center 
University of Southern California 
1450 Biggy Street, NRT 1506A 
Los Angeles, CA 90033 
wiemels@usc.edu 
 
Word count: main text 1493 words. 
 
Acknowledgements 
The authors would like to thank the Lundbeck Foundation, Clinical Research 
Fellowship granted to A.B.N. Research reported in this publication was supported by funding from 
the National Institutes of Health (grants R01CA175737, R01ES009137 and P50ES018172) and the 
Environmental Protection Agency (grant RD83615901) of the United States. The content is solely 
the responsibility of the authors and does not represent the official views of any funding agencies.  
	
	
2 
The biospecimens and/or data used in this study were obtained from the California 
Biobank Program at the California Department of Public Health, SIS request number 600, in 
accordance with Section 6555(b), 17 CCR. The authors acknowledge Robin Cooley and Marty 
Kharrazi of the California Department of Public Health for their assistance providing banked 
specimens and record linkage services for this portion of the study. This study used birth data 
obtained from the Center for Health Statistics and Informatics, California Department of Public 
Health. The California Department of Public Health is not responsible for the analyses, results, 
interpretations, or conclusions drawn by the authors regarding the birth data used in this publication. 
The collection of cancer incidence data used in this study was supported by the 
California Department of Public Health pursuant to California Health and Safety Code Section 
103885; Centers for Disease Control and Prevention’s National Program of Cancer Registries, 
under cooperative agreement 5NU58DP003862-04/DP003862; the National Cancer Institute’s 
Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C 
awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded 
to the University of Southern California, and contract HHSN261201000034C awarded to the Public 
Health Institute.  The ideas and opinions expressed herein are those of the author(s) and do not 
reflect the opinions of the State of California, Department of Public Health, the National Cancer 
Institute, and the Centers for Disease Control and Prevention or their Contractors and 
Subcontractors. 
 
 
Letter to the Editor  
Acute lymphoblastic leukemia (ALL) afflicts 2,250 children diagnosed annually in the United 
States (0-14 yrs).1 Modern treatment regimens cure approximately 90% of those afflicted, but 
survivors suffer from long-term sequelae.2 Epidemiologic evidence for ALL development points to 
a role for infection and immune development.3 Clinically diagnosed infections in the first year of 
life have been associated with a higher risk of childhood ALL,4,5 whereas increased exposure to 
common infections based on proxy measures of childhood social contacts (e.g., daycare attendance) 
may reduce risk.6 The role of neonatal immune development in ALL is further supported by the 
increased ALL risk in children delivered by elective cesarean section.7 Emerging evidence suggests 
that neonatal infection susceptibility is related to active immune suppression within the neonatal 
environment. A key regulator within perinatal immunity is arginase 2 (ARG2),8,9 which suppresses 
T-cells through an anti-inflammatory cascade resulting from arginine depletion.10 Given the 
function of ARG2 in neonatal immune function and response to early-life infections, we 
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investigated whether variation in ARG2 levels at birth may be associated with risk of developing 
ALL in childhood. For the current study, we selected a total of 137 children who were born in seven 
counties of California and diagnosed with ALL at the ages of 0-14 years during 2000-2009, as well 
as 500 cancer-free control children who were matched to the cases by birth year and county of birth 
(3 or 4 controls per case). We obtained data on cancer diagnosis from the California Cancer 
Registry, data on birth characteristics from the California Center for Health Statistics and 
Informatics, and archived neonatal blood spots from the California Biobank Program which is part 
of the Genetic Disease Screening Program. The blood spots, which were used in this study to 
measure newborn ARG2 levels, were leftover material from statewide disease screening in 
newborns. All available cases were obtained within the catchment time and space, along with 
appropriate matched controls chosen via a population-based registry. Our study protocol has been 
approved by the State of California Committee for the Protection of Human Subjects, and the 
institutional review boards at all agencies from which we obtained data or blood spots as well as the 
academic institutions involved (University of California, San Francisco and Berkeley, Yale 
University, University of Southern California). We obtained a 14-mm diameter blood spot on filter 
paper (also known as Guthrie card) collected via a heel-prick of the newborns, usually within two 
days after birth (median = 28 hours). These blood spots are stored at a central State archive under 
frozen (-20°C) conditions. For each subject, one third of a blood spot was excised and placed in 300 
µL of extraction buffer [PBS, pH 7.4, 0.5% Tween-20 and 2x complete protease inhibitor cocktail 
(Roche)], shaken at 600 rpm under room temperature for 1 hour and spun 30 sec at 20,000 x g. 
Extracts were assayed in duplicate and block randomized on 96-well plates, with each plate 
containing a 7-point standard ARG2 dilution in duplicate, and the same proportion of cases and 
controls and racial/ethnic groups. ARG2 was measured using enzyme-linked immunosorbent assay 
(ELISA) (MyBioSource). Serum-protein levels were determined using Pierce BCA protein assay.  
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Four parameter logistic regression was used to calculate the standard curves for each batch.  ARG2 
levels were estimated from standard curves.  ARG2 levels were averaged across duplicates and 
normalized to the sample-specific total serum-protein concentration. Categorical variables are 
shown using frequencies and percentages, and continuous variables (eg., age at neonatal blood 
collection) were summarized by median and interquartile range.  Baseline characteristics between 
cases and controls were compared using chi-square test for categorical variables and Wilcoxon rank 
sum test for age at neonatal blood collection. ARG2 levels were categorized into quartiles 
according to the distribution among controls. An unconditional multivariable mixed-effect logistic 
regression model with batch as a random variable was used to estimate the association between 
ARG2 level and risk of ALL, adjusting for birth characteristics (listed in Figure 1 legend). All 
analyses were conducted using SAS Version 9.4 (SAS Institute Inc., Cary, NC) with two-sided tests 
and a type I error of 5% as the threshold for statistical significance. A p-value for trend with 
increasing ARG2 was calculated by treating arginase quartile as an ordinal variable in the logistic 
regression model. Eight control samples were excluded due to a coefficient of variance greater than 
30% between duplicate ARG2 measurements. Cases and controls were similar with regard to sex, 
race/ethnicity, gestational age, birth weight, and birth order (Table 1).  Additional data on 
distribution of ARG2 in relationship with these covariates are presented in Supplementary Tables 1 
and 2. Compared with controls, ALL cases were more likely to be delivered by cesarean section 
(39% vs 28%, p=0.02) and were older at neonatal blood collection (median: 29 vs. 27 hours, 
p=0.01).  In addition, among controls, calendar age of the card was negatively correlated with 
ARG2 level (Spearman correlation coefficient = -0.20, p=0.0001).  The multivariable analysis 
suggested that the risk of childhood ALL increased by more than two-fold in subjects whose level 
of ARG2 at birth was in the 3rd or 4th quartile, compared to those whose ARG2 level was in the 
lowest quartile. The odds ratio was 2.20 (95% confidence interval (CI): 1.21 - 3.99, p=0.01) and 
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2.28 (95% CI: 1.28 - 4.07, p=0.01) for Q3 and Q4, respectively (Figure 1), with a significant trend: 
OR = 1.31 (95%CI: 1.10-1.57, p = 0.0021). This relationship did not change when samples were not 
adjusted for protein extraction levels (OR = 1.34; 95%CI:1.06-1.69, no correction for protein 
concentration). ARG2 levels were higher for children born with cesarean section among cases (P = 
0.06 by Wilcoxon rank test) and controls (P = 0.56), and the case-control relationship with ARG2 
was slightly weakened by removing all subjects with cesarean section birth, OR = 1.21(95%CI 
0.98-1.52, p = 0.07, trend test) (Supplementary Table 3) while the full dataset retained significance 
when adjusting for cesarean birth (Figure 1 and Supplementary Table 4). When the analysis was 
restricted to B cell only (100 cases), ARG2 retained significance, OR=1.22(95%CI 1.00-1.49, P = 
0.05, Supplementary Table 5). We therefore found that the higher neonatal ARG2 levels associated 
with a ALL later in childhood held true for the most common subtype of ALL: pre-B cell. Arginase 
has been reported to impact the immune system via its role in depletion of L-arginine, which may 
impair NO-mediated cytotoxicity, decrease TLR-4 mediated proinflammatory response and 
suppress T-cell function via downregulation of TCR-CD3ζ.8 Several studies have shown increased 
arginase production by myeloid-derived suppressor cells (MDSCs) in adult tumors leading to a 
suppressed response in the tumor immune microenvironment.11 Recently, a transitory presence of 
MDSCs has been identified in newborns, suggesting that these cells have an additional role of 
regulating immune suppression early in life.12 In addition, infection susceptibility in newborn mice 
has been associated with temporal presence of CD71+ immunosuppressive erythroid cells 
producing ARG2,13 which could impact the response to early infections known to affect risk of 
ALL.4,5 While higher ARG2 may be indicative of greater immunosuppression at birth, it is also 
possible that it is simply a marker of the level of early infant immune stimulation prior to Guthrie 
card blood sampling. Therefore, higher ARG2 levels could signify a naïve neonatal immune system 
due to lower prior microbial exposures,3 and those subjects with high ARG2 may react 
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inappropriately to new infections thereby stimulating leukemogenesis.4,5 Our group previously 
reported a deficit of IL-10 at birth among children who subsequently developed ALL, suggesting 
that a child’s baseline immune function at birth may affect his/her response to subsequent infectious 
exposures and leukemia risk.14 Recently this observation was expanded to additional cytokines.15 
Taken together with the current results, the evidence suggests that a dysregulated immune response 
around the time of birth may affect the responsiveness of the developing immune system and also 
provide a growth advantage for a preleukemic clone. Strengths of the study include the low 
likelihood for selection and information bias (population-based ascertainment of study subjects, no 
need to contact subjects for participation, preexisting data on important covariates through birth 
records) and the availability of archived newborn blood specimens for measurement of ARG2 level 
at birth. While samples that have been stored for longer time appeared to have lower ARG2 levels, 
our cases and controls were frequency matched on year of birth and hence the duration of sample 
storage. Nondifferential misclassification regarding ARG2 levels would likely have biased our 
results towards the null. In summary, the present study showed that a higher ARG2 level at birth 
was associated with statistically significant increased odds of developing ALL later in childhood. 
This finding suggests that immune changes related to ARG2 levels are evident long before the 
clinical manifestation of childhood leukemia.  Our results require validation and further 
investigation in larger studies of neonatal ARG2 that include detailed assessment of early childhood 
infections and autoimmune diseases. However, this novel finding contributes to increasing evidence 
for a role of immune dysregulation at birth in the development of childhood ALL.  
 
Disclosure of Conflicts of Interest 
The authors do not have any competing financial or other interests in the contents or interpretations 
presented within this manuscript. 
 
	
	
7 
Authorship Contributions 
A.B.N. performed experiments, analyzed data, and drafted the manuscript with JW; M.Z., A.D. 
performed experiments and A.D. conceived the study with J.W.; R.W. planned and conducted 
statistical analysis and co-wrote the sections on statistical analysis and results; H.H. ascertained and 
managed Guthrie Cards and laboratory activities; L.M., C.J., K.G., S.K., C.M., P.B. contributed to 
the analysis and reviewed the manuscript;  X.M. and J.W. designed the overall study, planned the 
analysis, and helped to draft the manuscript.  
	
	
8 
1.  Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood 
cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18(6):719–731. 
2.  Hudson MM, Ness KK, Gurney JG, et al. Clinical Ascertainment of Health Outcomes 
Among Adults Treated for Childhood Cancer. JAMA. 2013;309(22):2371. 
3.  Greaves M. A causal mechanismn for childhood acute lymphoblastic leukaemia. Nat Rev 
Cancer. 2018;18(8):471-484. 
4.  Chang JS, Tsai C-R, Tsai Y-W, Wiemels JL. Medically diagnosed infections and risk of 
childhood leukaemia: a population-based case–control study. Int J Epidemiol. 
2012;41(4):1050–1059. 
5.  Crouch S, Lightfoot T, Simpson J, Smith A, Ansell P, Roman E. Infectious Illness in 
Children Subsequently Diagnosed With Acute Lymphoblastic Leukemia: Modeling the 
Trends From Birth to Diagnosis. Am J Epidemiol. 2012;176(5):402–408. 
6.  Urayama KY, Buffler PA, Gallagher ER, Ayoob JM, Ma X. A meta-analysis of the 
association between day-care attendance and childhood acute lymphoblastic leukaemia. Int J 
Epidemiol. 2010;39(3):718–732. 
7.  Wang R, Wiemels JL, Metayer C, et al. Cesarean Section and Risk of Childhood Acute 
Lymphoblastic Leukemia in a Population-Based, Record-Linkage Study in California. Am J 
Epidemiol. 2017;185(2):96–105. 
8.  Munder M. Arginase: An emerging key player in the mammalian immune system: REVIEW. 
Br J Pharmacol. 2009;158(3):638–651. 
9.  Badurdeen S, Mulongo M, Berkley JA. Arginine depletion increases susceptibility to serious 
infections in preterm newborns. Pediatr Res. 2015;77(2):290–297. 
10.  McGovern N, Shin A, Low G, et al. Human fetal dendritic cells promote prenatal T-cell 
immune suppression through arginase-2. Nature. 2017;546(7660):662–666. 
11.  Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat 
Immunol. 2018;19(2):108–119. 
	
	
9 
12.  He YM, Li X, Perego M, et al. Transitory presence of myeloid-derived suppressor cells in 
neonates is critical for control of inflammation. Nat Med. 2018;24(2):224–231. 
13.  Elahi S, Ertelt JM, Kinder JM, et al. Immunosuppressive CD71+ erythroid cells compromise 
neonatal host defence against infection. Nature. 2013;504(7478):158–162. 
14.  Chang JS, Zhou M, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. Profound deficit 
of IL10 at birth in children who develop childhood acute lymphoblastic leukemia. Cancer 
Epidemiol Biomarkers Prev. 2011;20(8):1736–1740. 
15.  Søegaard SH, Rostgaard K, Skogstrand K, Wiemels JL, Schmiegelow K, Hjalgrim H. 
Neonatal inflammatory markers are associated with childhood b-cell precursor acute 
lymphoblastic Leukemia. Cancer Res. 2018;78(18):5458-5463. 
 
 
	
	
10 
 
Table 1. Characteristics of Childhood Acute Lymphoblastic Leukemia Cases and Controls 
 
	 	 Case	 	 Control	 	 p	
	 	 n	(%)	 	 n	(%)	 	 	
Total	 	 137	 	 492	 	 	
Sex	 	 	 	 	 	 	
	 Male	 78	(57)	 	 283	(58)	 	 0.9	
	 Female	 59	(43)	 	 209	(42)	 	 	
Race/ethnicity		 	 	 	 	 	 	
	 Hispanic	 74	(54)	 	 279	(57)	 	 0.85	
	 Non-Hispanic	White	 41	(30)	 	 139	(28)	 	 	
	 Other	 22	(16)	 	 74	(15)	 	 	
Gestational	age	(weeks)	 	 	 	 	 	
	 <37	 13	(9)	 	 46	(9)	 	 0.88	
	 37-41	 112	(82)	 	 397	(81)	 	 	
	 ≥42	 9	(7)	 	 26	(5)	 	 	
	 Unknown	 3	(2)	 	 23	(5)	 	 	
Birth	weight	(grams)	 	 	 	 	 	
	 <2500	 4	(3)	 	 19	(4)	 	 0.63	
	 2500-2999	 23	(17)	 	 74	(15)	 	 	
	 3000-3499	 57	(42)	 	 193	(39)	 	 	
	 3500-3999	 44	(32)	 	 153	(31)	 	 	
	 ≥4000	 9	(7)	 	 53	(11)	 	 	
Birth	order	 	 	 	 	 	 	
	 First	 55	(40)	 	 185	(38)	 	 0.8	
	 Second	 46	(34)	 	 165	(34)	 	 	
	 Third	or	higher	 36	(26)	 	 142	(29)	 	 	
Plurality	 	 	 	 	 	 	
	 Singleton	 131	(96)	 	 480	(98)	 	 0.23	
	 Multiple	 6	(4)	 	 12	(2)	 	 	
Delivery	mode	 	 	 	 	 	 	
	 Vaginal	delivery	 84	(61)	 	 354	(72)	 	 0.02	
	 Cesarean	delivery	 53	(39)	 	 138	(28)	 	 	
Year	of	birth	 	 	 	 	 	 	
	 2000-2002	 49	(36)	 	 173	(35)	 	 0.7	
	 2003-2005	 61	(45)	 	 206	(42)	 	 	
	 2006-2009	 27	(20)	 	 113	(23)	 	 	
Age	at	neonatal	blood	collection	(hours)	 	 	 	 	 	
	 Median	(interquartile	range)	 29	(25-40)	 	 27(23-36)	 	 0.01	
Mother’s	age	at	delivery	(years)	 	 	 	 	 	
	 <25	 30	(22)	 	 149	(30)	 	 0.15	
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	 25-34	 85	(62)	 	 269	(55)	 	 	
	 ≥35	 22	(16)	 	 74	(15)	 	 	
Mother’s	place	of	birth	 	 	 	 	 	
	 United	States	 78	(57)	 	 262	(53)	 	 0.44	
	 Other	 59	(43)	 	 230	(47)	 	 	
 
 
 
 
 
Figure Legends: 
Figure 1. Adjusted odds ratios for quartiles of neonatal Arginase 2 associated with childhood acute 
lymphoblastic leukemia (ALL) (n=137 cases, n=492 controls). Adjusted for sex, race/ethnicity 
(non-Hispanic white, Hispanic white and other), birth weight (<2500, 2500-2999, 3000-3499, 3500-
3999, ≥4000), birth order (first, second, third or higher), plurality (singleton, multiple), delivery 
mode (vaginal, cesarean delivery), year of birth, age at neonatal blood collection, mother’s age at 
delivery (<25, 25-34, ≥35), and mother’s place of birth (United States, other). Abbreviations: OR: 
odds ratio; LCL – lower 95% confidence limit; UCL – upper 95% confidence limit. 
 
Supplementary Table 1: ARG2 levels by case and control status, and within quartiles (protein-corrected)
ARG2 n median mean range median mean range
overall 137 8.0 12.1 0.83-242.3 492 6.9 11.6 1.0-279.7
Q1 21 3.2 3.0 0.83-4.2 123 3.2 3.2 1.0-4.6
Q2 29 5.7 5.7 4.7-6.7 123 5.7 5.7 4.6-6.9
Q3 44 8.5 8.6 6.9-10.7 123 8.5 8.7 6.9-10.9
Q4 43 14.2 24.3 10.9-242.3 123 16.5 28.6 10.9-279.7
Supplementary Table 2: ARG2 levels (protein corrected) by demographic factors
median mean range median mean range
race White 8.6 10.8 3.2-42.9 7.2 11.1 1.4-192.9
Hispanic 8.0 10.0 0.8-45.3 7.5 12.6 1.0-279.7
Other 7.7 21.4 1.1-242.3 5.7 8.4 1.5-61.9
Sex Female 7.9 9.3 0.8-39.1 6.8 12.0 1.2-279.7
Male 8.3 14.1 1.5-242.3 7.1 11.2 1.0-222.2
age at collection mean (SD)
   (hours)
birthweight (g) <2500 10.9 10.2 4.8-14.2 7.3 11.1 3.2-61.9
2500-2999 7.5 10.9 1.1-45.3 6.9 13.8 2.0-279.7
3000-3499 9.1 16.3 2.6-242.3 6.8 11.9 1.0-49.6
3500-3999 7.7 8.2 0.83-22.6 6.7 9.2 1.5-49.6
4000+ 7.3 7.6 4.2-13.5 7.9 13.9 2.1-222.2
gestational age <37 10.7 32.5 4.8-242.3 6.6 15.7 2.0-279.7
37-41 7.6 9.9 0.83-68.7 6.8 10.7 1.2-192.9
42+ 9.6 9.3 3.5-13.1 7.1 16.9 1.0-192.9
Unknown 11.8 11.7 11.2-12.0 9.3 11.8 1.6-30.5
Plurality No 8.0 12.0 0.83-242.3 6.9 11.6 1.0-279.7
Yes 9.7 14.1 2.5-39.2 7.1 8.3 1.2-25.3
cases controls
ARG2 controls (N = 492)ARG2 cases (N = 137)
birth order 1 8.0 10.9 1.1-68.7 7.2 13.7 1.5-279.7
2 8.0 14.1 0.83-242.3 6.9 9.4 1.8-84.4
3+ 8.4 11.2 1.8-45.4 6.3 11.3 1.0-192.9
C-section No 7.6 9.2 1.1-42.9 6.8 12.7 1.5-279.7
Yes 9.6 16.6 0.83-242.3 7.2 8.5 1.0-45.5
Mother’s age <25 9.2 10.2 2.6-22.9 6.7 11.9 1.5-192.9
25-34 8.0 10.6 0.83-68.7 7.0 11.7 1.0-279.7
35+ 7.5 20.3 2.7-242.3 6.9 10.4 1.5-84.4
Mother’s birthplace US 8.0 9.8 1.5-42.9 6.8 10.2 1.5-192.9
Other 8.4 15.1 0.83-242.3 6.9 13.1 1.0-279.7
Year of birth 2000 7.1 7.5 3.3-15.5 7.7 11.4 1.7-93.0
2001 7.2 10.0 0.83-68.7 8.7 19.2 1.5-279.7
2002 10.5 13.9 5.3-45.4 7.9 13.9 3.3-192.9
2003 9.7 23.8 4.7-242.3 7.5 9.5 2.6-37.6
2004 9.1 10.6 1.5-39.1 5.5 9.9 1.0-135.7
2005 6.3 12.4 3.1-42.9 5.8 12.4 1.5-222.2
2006 7.6 9.5 3.1-42.9 6.0 8.0 1.7-30.5
2007 6.1 7.6 2.5-30.6 5.9 7.2 2.2-18.7
2008 7.7 9.6 3.9-20.3 5.9 7.6 1.8-22.6
2009 4.7 4.7 2.0-7.3
All values are expressed as ng Arginase-2 per ug protein X 10
Supplementary Table 3:  Case-control resuts for ARG2 levels while exclude participants delivered by c-section, and quartiles cutoffs based on all controls (n=84 cases, n=354 controls)
Case Control OR 95% CI p
ARG2 n (%) n (%)
1st quartile 12 (14.3) 84 (23.7) 1
2nd quartile 21 (25.0) 95 (26.8) 1.48 0.67-3.31 0.33
3rd quartile 29 (34.5) 84 (23.7) 2.39 1.10-5.17 0.03
4th quartile 22 (26.2) 91 (25.7) 1.77 0.82-3.81 0.14
Trend 1.22 0.98-1.52 0.07
Supplementary Table 4: Case-control resuts for ARG2 levels with all participants adjusted for c-section, and without adjustment (n=137 cases, n=492 controls)
A: with C-section B: without C-section
ARG2 OR 95% CI p OR 95% CI p
1st quartile 1 1
2nd quartile 1.49 0.79-2.80 0.26 1.42 0.76-2.66 0.28
3rd quartile 2.2 1.21-3.99 0.01 2.17 1.20-3.92 0.01
4th quartile 2.28 1.28-4.07 0.01 2.26 1.27-4.01 0.01
Trend 1.31 1.10-1.57 <0.01 1.32 1.11-1.57 <0.01
Adjusted odds ratios for quartiles of neonatal Arginase 2 associated with childhood acute lymphoblastic leukemia (ALL) (n=137 cases, n=492 controls). 
Adjusted for sex, race/ethnicity (non-Hispanic white, Hispanic white and other), birth weight (<2500, 2500-2999, 3000-3499, 3500-3999, ≥4000), 
birth order (first, second, third or higher), plurality (singleton, multiple), delivery mode (A  only: vaginal, cesarean delivery), year of birth, age at neonatal blood collection,
mother’s age at delivery (<25, 25-34, ≥35), and mother’s place of  birth (United States, other). 
Supplementary Table 5: Case control results for ARG2 levels for B-cell ALL only (ICD-O-3:9836, case=100, control=492)
Case Control OR 95% CI p
ARG2 n (%) n (%)
1st quartile 15(15.0) 123(25.0) 1
2nd quartile 25(25.0) 123(25.0) 1.82 0.88-3.75 0.11
3rd quartile 34(34.0) 123(25.0) 2.36 1.18-4.71 0.02
4th quartile 26(26.0) 123(25.0) 1.91 0.93-3.93 0.08
Trend 1.22 1.00-1.49 0.05
Adjusted odds ratios for quartiles of neonatal Arginase 2 associated with childhood acute lymphoblastic leukemia (ALL) (n=137 cases, n=492 controls). 
Adjusted for sex, race/ethnicity (non-Hispanic white, Hispanic white and other), birth weight (<2500, 2500-2999, 3000-3499, 3500-3999, ≥4000), 
birth order (first, second, third or higher), plurality (singleton, multiple), delivery mode (vaginal, cesarean delivery), year of birth, age at neonatal blood collection,
mother’s age at delivery (<25, 25-34, ≥35), and mother’s place of  birth (United States, other). 
